Accelerated bone loss in patients with cancer is a frequent problem that may result from invasion of the cancer to bone, paraneoplastic tumor proteins, and/or hormonal therapies utilized for cancer treatment. Patients with osteolytic bone disease from multiple myeloma and bone metastases from solid tumors may develop a vicious cycle of bone destruction involving both osteolytic and osteoblastic effects. Consequently, a variety of skeletal-related events (SREs) may occur, including pathological fractures, hypercalcemia, spinal cord compression, and the need for surgical intervention and radiation therapy.
Methods
This article reviews the results of trials that investigated the safety and efficacy of pharmacologic agents, including bisphosphonates and denosumab, for treatment of bone metastases. This analysis is derived from an assessment of the medical literature.
Results
Beneficial systemic therapies for bone metastases have been developed to decrease SREs. Possible antitumor effects of the bisphosphonates are explored. In addition, the utility of markers of bone turnover in relation to response to therapy and survival, the safety and toxicity of bone-targeted therapies, treatment guidelines, and economic considerations are also discussed.
Conclusions
Effective systemic therapies for metastatic bone disease are available. Ongoing and future research projects in this field are also presented.
References
1.
LiptonA.. Bone loss prevention in cancer: new developments and perspectives.Semin Oncol.2010; 37(suppl 1): S1–S2.
2.
ColemanR.E.. Metastatic bone disease: clinical features, pathophysiology and treatment strategies.Cancer Treat Rev.2001; 27(3): 165–176.
3.
HarveyH.A., CreamL.R.. Biology of bone metastases: causes and consequences.Clin Breast Cancer.2007; 7(suppl 1): S7–S13.
4.
MundyG.R.. Metastasis to bone: causes, consequences and therapeutic opportunities.Natl Rev Cancer.2002; 2(8): 584–593.
5.
RoodmanG.D.. Mechanisms of bone metastasis.N Engl J Med.2004; 350(16): 1655–1664.
6.
LiptonA.. Future treatment of bone metastases.Clin Cancer Res.2006; 12(20 Pt 2): 6305S–6308S.
7.
LaceyD.L., TimmsE., TanH.L.. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.Cell.1998; 93(2): 165–176.
8.
SaadF., LiptonA., CookR.. Pathologic fractures correlate with reduced survival in patients with malignant bone disease.Cancer.2007; 110(8): 1860–1867.
9.
SaadF., GleasonD.M., MurrayR.. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.J Natl Cancer Inst.2004; 96(11): 879–882.
RosenL.S., GordonD., TchekmedyianN.S.. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial.Cancer.2004; 100(12): 2613–2621.
12.
LiptonA., TheriaultR.L., HortobagyiG.N.. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.Cancer.2000; 88(5): 1082–1090.
13.
FleischH.. Development of bisphosphonates.Breast Cancer Res.2002; 4(1): 30–34.
14.
GreenJ., ClézardinP.. The molecular basis of bisphosphonate activity: a preclinical perspective.Semin Oncol.2010; 37(suppl 1): S3–S11.
RosenL., HarlandS.J., OosterlinckW.. Broad clinical activity of zoledronic acid in osteolytic to osteoblastic bone lesions in patients with a broad range of solid tumors.Am J Clin Oncol.2002; 25(6 suppl 1): S19–S24.
17.
FornierM.N.. Denosumab: second chapter in controlling bone metastases or a new book?J Clin Oncol.2010; 28(35): 5127–5131.
18.
MortimerJ.E., PalS.K.. Safety considerations for use of bone-targeted agents in patients with cancer.Semin Oncol.2010; 37(suppl 1): S66–S72.
19.
EllisG.K., BoneH.G., ChlebowskiR.. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmeta-static breast cancer.J Clin Oncol.2008; 26(30): 4875–4882.
20.
PavlakisN., SchmidtR., StocklerM.. Bisphosphonates for breast cancer.Cochrane Database Syst Rev.2005; 3: CD003474.
21.
KohnoN., AogiK., MinamiH.. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.J Clin Oncol.2005; 23(15): 3314–3321.
22.
RosenL.S., GordonD., KaminskiM.. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter comparative trial.Cancer.2003; 98(8): 1735–1744.
23.
RosenL.S., GordonD.H., DuganWJr. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.Cancer.2004; 100(1): 36–43.
24.
StopeckA.T., LiptonA., BodyJ.J.. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.J Clin Oncol.2010; 28(35): 5132–5139.
25.
ZarogoulidisK., BoutsikouE., ZarogoulidisP.. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastases.Int J Cancer.2009; 125(7): 1705–1709.
26.
HenryD.H., CostaL., GoldwasserF.. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.J Clin Oncol.2011; 29(9): 1125–1132.
27.
SaadF., EasthamJ.. Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer.Urology.2010; 76(5): 1175–1181.
28.
SaadF., EasthamJ.. Maintaining bone health in prostate cancer throughout the disease continuum.Semin Oncol.2010; 37(suppl 1): S30–S37.
29.
FizaziK., CarducciM., SmithM.. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.Lancet.2011; 377(9768): 813–822.
30.
SaadF., EasthamJ.A.. Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer.Semin Oncol.2010; 37(suppl 1): S38–S44.
31.
SaadF., LiptonA.. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.BJU Int.2005; 96(7): 964–969.
32.
LiptonA., ZhengM., SeamanJ.. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.Cancer.2003; 98(5): 962–969.
33.
KijimaT., FujiiY., SuyamaT.. Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate.BJU Int.2009; 103(5): 620–624.
34.
MuldersP.F.A., MillerK., TchekmedyianN.S.. Long-term reduction in risk of skeletal complications with zoledronic acid in patients with advanced renal cell carcinoma or bladder cancer. Presented at the 22nd Annual European Association of Urology Congress; March 21-24, 2007; Berlin, Germany. Abstract No. 971.
35.
ZaghloulM.S., BoutrusR., El-HossienyH.. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer.Int J Clin Oncol.2010; 15(4): 382–389.
36.
BerensonJ.R.. Therapeutic options in the management of myeloma bone disease.Semin Oncol.2010; 37(suppl 1): S20–S29.
37.
TerposE., BerensonJ., CookR.J.. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease.Leukemia.2010; 24(5): 1043–1049.
38.
LahtinenR., LaaksoM., PalvaI.. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group.Lancet.1992; 340(8827): 1049–1052.
39.
BerensonJ.R., LichtensteinA., PorterL.. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.N Engl J Med.1996; 334(8): 488–493.
40.
RosenL.S., GordonD., KaminskiM.. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind comparative trial.Cancer J.2001; 7(5): 377–387.
41.
MajorP., LortholaryA., HonJ.. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.J Clin Oncol.2001; 19(2): 558–567.
42.
PecherstorferM., SteinhauerE.U., RizzoliR.. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate.Support Care Cancer.2003; 11(8): 539–547.
GalloM., De LucaA., LamuraL.. Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer.Ann Oncol.2012; 23(3): 597–604.
45.
ChlebowskiR.T., ChenZ., CauleyJ.A.. Oral bisphosphonate use and breast cancer incidence in postmenopausal women.J Clin Oncol.2010; 28(22): 3582–3590.
46.
RennertG., PinchevM., RennertH.S.. Use of bisphosphonates and risk of postmenopausal breast cancer.J Clin Oncol.2010; 28(22): 3577–3581.
47.
RennertG., PinchevM., RennertH.S.. Use of bisphosphonates and reduced risk of colorectal cancer.J Clin Oncol.2011; 29(9): 1146–1150.
48.
HaT.C., LiH.. Meta-analysis of clodronate and breast cancer survival.Br J Cancer.2007; 96(12): 1796–1801.
49.
GnantM., MlineritschB., SchippingerW.. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.N Engl J Med.2009; 360(7): 679–691.
50.
GnantM., MlineritschB., StoegerH.. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.Lancet Oncol.2011; 12(7): 631–641.
51.
ColemanR., BundredN., De BoerR.. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant le-trozole: Z-FAST, ZO-FAST, and E-ZO-FAST. Poster presented at 32nd Annual San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, Texas.
52.
MonseesG.M., MaloneK.E., TangM.T.. Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer.J Natl Cancer Inst.2011; 103(23): 1752–1760.
WysowskiD.K.. Reports of esophageal cancer with oral bisphosphonate use.N Engl J Med.2009; 360(1): 89–90.
55.
GreenJ., CzannerG., ReevesG.. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort.BMJ.2010; 341: c4444.
56.
CardwellC.R., AbnetC.C., CantwellM.M.. Exposure to oral bisphosphonates and risk of esophageal cancer.JAMA.2010; 304(6): 657–663.
57.
AbrahamsenB., EikenP., EastellR.. More on reports of esophageal cancer with oral bisphosphonate use.N Engl J Med.2009; 360(17): 1789–1792.
58.
LowesR.. FDA studying link between bisphosphonates, esophageal cancer.Medscape News Today. July 21, 2001. http://www.medscape.com/viewarticle/746793. Accessed December 22, 2011.
59.
ColemanR.E., MajorP., LiptonA.. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.J Clin Oncol.2005; 23(22): 4925–4935.
60.
LiptonA., CookR., SaadF.. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.Cancer.2008; 113(1): 193–201.
61.
FizaziK., LiptonA., MarietteX.. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.J Clin Oncol.2009; 27(10): 1564–1571.
62.
HillnerB.E., IngleJ.N., BerensonJ.R.. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer.J Clin Oncol.2000; 18(6): 1378–1391.
63.
Van PoznakC.H., TeminS., YeeG.C.. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.J Clin Oncol.2011; 29(9): 1221–1227.
64.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer. v.2.2011: MS37-MS39. Available at: http://www.nccn.org. Fort Washington, PA: National Comprehensive Cancer Network, Inc; 2011. Accessed February 3, 2012.
65.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer. v.4.2011: MS22-MS23. Available at: http://www.nccn.org. Fort Washington, PA: National Comprehensive Cancer Network, Inc; 2011. Accessed February 3, 2012.
66.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer. v.2.2011: MS11-MS12. Available at: http://www.nccn.org. Fort Washington, PA: National Comprehensive Cancer Network, Inc; 2011. Accessed February 3, 2012.
67.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: multiple myeloma. v.1.2012: MS24-MS25. Available at: http://www.nccn.org. Fort Washington, PA: National Comprehensive Cancer Network, Inc; 2011. Accessed February 3, 2012.
68.
DeleaT.E., McKiernanJ., BrandmanJ.. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer.J Thorac Oncol.2006; 1(6): 571–576.
69.
DeleaT., LangerC., McKiernanJ.. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.Oncology.2004; 67(5-6): 390–396.
70.
LageM.J., BarberB.L., HarrisonD.J.. The cost of treating skeletal-related events in patients with prostate cancer.Am J Manag Care.2008; 14(5): 317–322.
71.
DeleaT., McKiernanJ., BrandmanJ.. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice.J Support Oncol.2006; 4(7): 341–347.
WestH.. Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: incremental benefit, debatable value.J Clin Oncol.2011; 29(9): 1095–1098.
74.
SaadF., LiptonA.. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.Cancer Treat Rev.2010; 36(2): 177–184.
75.
AraujoJ., LogothetisC.. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.Cancer Treat Rev.2010; 36(6): 492–500.
76.
JensenA.B., WynneC., RamirezG.. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial.Clin Breast Cancer.2010; 10(6): 452–458.
77.
HuangE.H., SinghB., CristofanilliM.. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer.J Surg Res.2009; 155(2): 231–236.
78.
BaselgaJ., RothenbergM.L., TaberneroJ.. TGF-beta signaling-related markers in cancer patients with bone metastasis.Biomarkers.2008; 13(2): 217–236.
79.
DuivenvoordenW.C., HirteH.W., SinghG.. Transforming growth factor beta 1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells.Clin Exp Metastasis.1999; 17(1): 27–34.
